TwiFlow Thrombectomy Catheter sYstem for Acute Pulmonary Embolism

Status Not yet recruiting

Clinical Trial Summary

As a multicenter prospective single-arm clinical study, the investigators plan to recruit patients with acute pulmonary intravascular embolization from nationwide multi-center hospital organizations in China. The investigators use the production of transcatheter pulmonary artery bolt system which named 'TwiFlow Thrombectomy Catheter System' developed by the MorningSide (NanTong) medical device Co., LTD. on pulmonary artery interventional therapy to evaluating the efficacy and safety of this novel system in the treatment of patients with pulmonary intravascular embolization disease.

Clinical Trial Description

As a multicenter prospective single-arm clinical study, the investigators plan to evaluate the new production's efficacy and safety which named 'TwiFlow-Thrombectomy Catheter System'. This study will be carried out in nationwide multi-center hospital organizations in China. According to the statistical principle, the sample size of this study was estimated, and the final number of selected cases was 127. After screening, all subjects will be treated with transcatheter pulmonary artery thrombectomy system, and clinical follow-up will be conducted at 48 hours, 14 days and 30 days after surgery. Right Ventricular/Left Ventricular decline from baseline to 48 hours after surgery and the incidence of major adverse events (MAE) within 48 hours after surgery were used as primary endpoints. In instrument performance evaluation, the success rate of surgery, postoperative immediate target lesion embolus removal efficiency, pulmonary artery pressure changes before and after operation value, values of arterial oxygen partial pressure changes before and 14 days after operation, death rates related to the equipment in 48 hours after surgery, incident rate of bleeding in 48 hours after operation, postoperative clinical deterioration rate in 48 hours after surgery, postoperative pulmonary vascular injury incidence in 48 hours after surgery, the incidence of heart damage injury in 48 hours after surgery, all-cause death rate in 30 days after surgery, and symptomatic Pulmonary Embolization recurrence rate in 30 days after surgery were secondary endpoints. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05792397
Study type	Interventional
Source	Morningside (Nantong) Medical Co.,Ltd
Contact	Ni Linyan, Manager
Phone	+8613661929821
Email	lyni@siriusmed.cn
Status	Not yet recruiting
Phase	N/A
Start date	May 1, 2023
Completion date	May 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00519506` - A Phase II Study to Evaluate the Efficacy of ThromboView® in the Detection of Pulmonary Emboli	Phase 2
Not yet recruiting	`NCT04110275` - Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)	Phase 2
Completed	`NCT05318092` - Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary Embolism	N/A
Completed	`NCT01604538` - Italian Pulmonary Embolism Registry - IPER	N/A
Completed	`NCT03631810` - Contemporary Clinical Management Of Acute Pulmonary Embolism
Recruiting	`NCT03504007` - Registry of Patients Prescribed Anticoagulation
Completed	`NCT01513759` - Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy	Phase 3
Completed	`NCT03108833` - A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism	Phase 2
Completed	`NCT04037423` - European Database on Catheter-directed Treatment of Pulmonary Embolism.
Not yet recruiting	`NCT06189313` - CLEANer Aspiration for Pulmonary Embolism	N/A
Not yet recruiting	`NCT05469724` - Clinical Pulmonary Embolism
Completed	`NCT01014156` - Epoprostenol in Pulmonary Embolism	Phase 4
Recruiting	`NCT06038630` - 129Xe MRI Cardiopulmonary	Phase 2
Recruiting	`NCT06192199` - The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism
Recruiting	`NCT04757129` - Changes of Cardiopulmonary Function After Thrombolysis in Patients With Pulmonary Embolism
Completed	`NCT03966079` - Thrombolysis Endovascular Treatment of Pulmonary Embolism	Phase 3
Recruiting	`NCT03916302` - Pulmonary Embolism WArsaw REgistry
Recruiting	`NCT06062329` - SYMPHONY-PE Study for Treatment of Pulmonary Embolism	N/A
Not yet recruiting	`NCT04480892` - Fibrinolytic Deficit in Patients With Acute PE
Enrolling by invitation	`NCT04047784` - Pilot Study to Evaluate the Role of EBUS in the Diagnosis of Acute PE in Critically Ill Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

TwiFlow Thrombectomy Catheter sYstem for Acute Pulmonary Embolism (Twi-TYPE Study) — Twi-TYPE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms